 Moneycontrol.com |
Glenmark starts Revamilast Phase IIb trials
Pharmaceutical Business Review Indian drug maker Glenmark Pharmaceuticals has started Phase IIb trials to evaluate Revamilast (GRC 4039) as a treatment for inflammatory disorders like rheumatoid arthritis (RA) and asthma. The trials aim to determine the safety and efficacy profile … Glenmark starts Phase-IIb human trials of Revamilast molecule Glenmark starts phase IIb human trials of molecule Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule … |
View full post on asthma – Google News